John H. Tucker is the chief executive officer of scPharmaceuticals. Prior to scPharmaceuticals, Mr. Tucker served as chief executive officer of Alcresta, developer of enzyme-based products for patients with acute and chronic diseases. While at Alcresta he led regulatory and financing strategies leading to its first product approval and increased valuation. Prior to Alcresta, he served as senior vice president and chief commercial officer of Incline Therapeutics, a hospital-focused specialty pharmaceutical company. There, he developed and drove the overall commercial strategy in support of the company’s lead product, IONSYS™, resulting in a $390 million purchase of Incline by The Medicines Company. He joined Incline from AMAG Pharmaceuticals, where he was senior vice president, commercial operations, responsible for all sales and marketing activities for the company. Previously, as president, U.S. operations at Basilea Pharmaceuticals, Mr. Tucker developed the strategy and organization for the planned launch of a hospital-focused product and led the company’s commercial development team. Prior to Basilea, Mr. Tucker was executive vice president, sales and marketing at Indevus Pharmaceuticals. Earlier in his career, he held a variety of both hospital and retail-based sales and marketing positions with increasing levels of responsibility at Ortho-McNeil Pharmaceuticals, ALZA Corporation, VIVUS and UCB Pharma. Mr. Tucker holds a B.A. from Plymouth State College and an MBA from New Hampshire College.
Mr. Ceesay brings extensive experience in the launch and growth of innovative therapeutic products and a strong track record in leading global commercial teams and development oriented organizations to commercial stage companies. Prior to joining scPharmaceuticals, Mr. Ceesay served as vice president, sales, marketing, and commercial operations at Keryx Biopharmaceuticals where he developed the commercial organization and strategy for the company’s inaugural product Auryxia®. Prior to his career at Keryx, Mr. Ceesay spent four years at Ironwood Pharmaceuticals as vice president, marketing, where he led the launch of the company’s inaugural product Linzess® and held responsibility for the management of the U.S. P&L, leadership of the Linzess® brand team and co-promotion collaboration with Forest Laboratories/Allergan. Mr. Ceesay also spent eight years at Genzyme/Sanofi, initially as a field sales specialist and ultimately as the director, Renal Global Marketing, in which capacity he led the global launch of Renvela® and held global marketing responsibility for the company’s renal franchise. Mr. Ceesay holds a bachelor’s degree from Ithaca College, and a Masters of Business Administration from Suffolk University’s Sawyer School of Management.
Mr. DellaGatta is a senior level medical device executive with over 25 years experience in start-up, mid-size, and large companies including C.R. Bard, Johnson and Johnson (Ethicon Endosurgery Div.) and Endologix, Inc. Most recently, Mr. DellaGatta served as director of US operations at Novocure, a multi-national oncology company with breakthrough technology in the treatment of glioblastoma. He has successfully moved start-up companies from early stage development to commercialization resulting in two acquisitions and two IPO’s, one with a current market cap of $1B (ELGX). His product experiences include guidewires, implantable stent-grafts, microfluidic embryo culture systems, sterile disposable and re-usable medical devices, surgical instruments and durable medical equipment serving the urology, laparoscopy, general surgery, in-vitro fertilization and oncology disciplines. He has a BS in Industrial Engineering from Worcester Polytechnic Institute.
Mr. Duane is a senior level quality executive with over 25 years experience in the biotech/pharmaceutical industry, most recently as the senior director/site quality head at Pfizer’s BioPharmaceutical facility in Andover, MA. He has held management positions in various areas of quality and manufacturing with Serono, Genetics Institute, Wyeth BioPharma, and Pfizer. Mr. Duane has experience in start-up manufacturing facilities in the US, as well as Ireland, Spain and Sweden, leading to regulatory approval for those facilities. He has extensive experience in preparing for and managing regulatory agency inspections in the US and abroad. Mr. Duane has also acted as a consultant for several companies in the greater Boston area. His product experience includes recombinant antihemophilic factors (Recombinate, ReFacto, and BeneFIX), vaccines (Prevenar 13), and bone graft products (InductOs, INFUSE). Mr. Duane has a BS in Biology/Medical Technology from the University of Connecticut.
Mr. Hirsch has over 15 years of commercial leadership experience most recently at Cubist Pharmaceuticals, Inc. where over 11 years he held positions of increasing commercial leadership responsibilities. In his most recent role as senior director of market access, he built and led the strategic account and managed care field teams in support of the Cubist portfolio of anti-infective products. Mr. Hirsch was responsible for access strategy and field deployment across a wide range of customers, including integrated delivery networks, hospital systems, payors, long term care and outpatient customers, accountable for greater than $1B in revenue. Before joining Cubist, Mr. Hirsch had successful sales roles at MedImmune, Inc. as a biotechnology sales specialist and at Xerox Corporation. Mr. Hirsch received his Bachelor’s degree in Psychology from American University in Washington DC.
Troy Ignelzi is a senior financial executive with more than 20 years experience in finance, operations and business development with start-up and established companies. Mr. Ignelzi has raised over $300 million in private/public equity and debt, in-licensed commercial technology and completed extensive investor outreach. Prior to scPharmaceuticals, Troy served as a member of the executive leadership teams at Juventas Therapeutics, Esperion Therapeutics (ESPR) and Insys Therapeutics (INSY) where he successfully led various equity and debt financings to fund pharmaceutical and drug device development from pre-IND through commercialization Troy holds a B.S. Accounting from Ferris State University, MI.
Dr. Myers has 20 years of experience in the life science and in vitro diagnostics (IVD) industries across multiple research, product development, and program management roles. She was most recently vice president, strategic alliances at BG Medicine Inc. where she managed the strategic and operational aspects of a $30 million multi-company alliance focused on cardiovascular disease, including a 7000 subject, innovative real-world clinical study conducted in partnership with Humana. Prior to joining BG Medicine, Dr. Myers was the vice president science and technology at Biotage AB where she successfully led the development of multiple research collaborations focused on development and validation of biomarker tests for the clinical market. Dr. Myers has also held senior research and product development roles at Applied Biosytems and Schleicher and Schuell. Dr. Myers earned her PhD at The Ohio State University from the Department of Pathology in the College of Medicine. She received her undergraduate degree in Biology and Chemistry from Heidelberg College.
Ms. Nokes is a senior level finance executive with over 15 years of experience, primarily in the life science industry. Ms. Nokes joined scPharmaceuticals from BG Medicine, Inc., a publicly traded medical device company where she was director of accounting. At BG Medicine, Ms. Nokes assisted in several rounds of financing from various sources culminating in the initial public offering in early 2011. She was instrumental in transformation of the finance organization from privately held to public, including SEC reporting and the implementation of Sarbanes Oxley. Prior to BG Medicine, Ms. Nokes held positions within Oak Industries, Inc., a publicly traded supplier of components to the communications industry, and PriceWaterhouseCoopers, where she began her career. She received her BS in Accounting from the Carroll School of Management at Boston College and a MS in Finance from Bentley University.
Dr Rheingold is a senior level pharmaceutical executive with over 35 years experience in the development of pharmaceutical formulations. His experience includes working with global pharmaceutical manufacturers, start-up companies, generic companies and contract manufacturers. Dr. Rheingold’s experience includes new product formulation development, scale-up, process start-up, optimization, troubleshooting and product launches. Dr Rheingold is an FDA-recognized expert in formulation development and technology transfer. Dr. Rheingold’s careers included prior responsibilities as VP of Pharmaceutical Development at Tobira Therapeutics and Barrier Therapeutics. Additionally he held senior positions with responsibility for pharmaceutical development at Organon, Hoffmann-La Roche, Bristol-Myers Squibb and Lederle Laboratories. He received his BS in Biology from the State University of New York at Stony Brook and his MS and PhD in Pharmaceutical Sciences from the University of Connecticut.
Dr. Zugasti is a product development engineer and program manager with more than 15 years experience in medical device design and manufacturing, as well as pharmaceutical R&D companies. Prior to joining scPharmaceuticals he served as senior engineer at Springleaf Therapeutics and before that was a senior consultant at a medical product design consultancy (Sagentia) and an engineering group leader at TransForm Pharmaceuticals (a J&J company). He also held engineering positions at medical device companies such as Diagnostic Ultrasound Inc., a medical portable ultrasound device manufacturer. Dr. Zugasti holds numerous patents and applications related to consumer and medical products as well as laboratory automation systems. He received his B.S., M.S. and Ph.D. degrees in Mechanical Engineering from MIT. At scPharmaceuticals, Dr. Zugasti leads the engineering and supplier management efforts related to the development of subcutaneous drug delivery devices.